What Serum Life Sciences does

Serum Life Sciences Ltd (SLS) is a wholly owned UK subsidiary of Serum Institute of India Pvt. Ltd (SIIPL), the world's largest vaccine manufacturer by number of doses produced and sold globally, and part of the Cyrus Poonawalla Group. Headquartered in London with a registered presence of 19 UK-based employees, SLS functions primarily as the UK Marketing Authorisation Holder and commercial/regulatory arm for SIIPL's vaccine and diagnostic portfolio, facilitating supply to the UK market and global immunisation programmes through partnerships with UN agencies including UNICEF, PAHO, Gavi, and MSF.

SLS's product portfolio spans diagnostics and vaccines manufactured by the parent. The flagship proprietary product is SIILTIBCY®, a novel intradermal tuberculosis diagnostic skin test using Mycobacterium tuberculosis derived antigens (rdESAT-6 and rCFP-10), approved by the MHRA in November 2025 and the European Commission in February 2025. Other commercialised products in the broader SIIPL portfolio that flow through SLS include the R21/Matrix-M™ malaria vaccine (WHO-recommended October 2023, first African shipment May 2024), COVOVAX™ (WHO Emergency Use Listing December 2021), COVISHIELD (AstraZeneca-partnered COVID-19 vaccine), BCG vaccines under an exclusive global supply arrangement with ImmunityBio, and a broad routine childhood vaccine portfolio (DTP, MMR, Hib, Hepatitis B). Core underlying technology includes Novavax-licensed Matrix-M saponin-based adjuvant technology and antigen-based vaccine platforms developed at parent-level manufacturing facilities in Pune, India.

Commercially, SLS operates an enterprise-focused go-to-market model targeting government health systems, UN procurement agencies, and institutional buyers, leveraging the parent's manufacturing scale of over 1.5 billion doses annually and global distribution reaching 145+ countries (170 via WHO prequalification). Revenue mechanics are product sales-driven with a £3-per-dose ceiling committed for low- and middle-income countries via the Gavi COVAX AMC mechanism. The entity has no disclosed revenue figures and operates with a cost structure dominated by regulatory affairs, partnership management, and a £50 million committed investment in the Cyrus Poonawalla Vaccines Research Building at the University of Oxford, signalling a long-term UK-based R&D and capacity-building footprint rather than standalone commercial scale.

Name

Serum Life Sciences

Legal name

Serum Life Sciences Ltd

Website

https://silsuk.com

Company type

Private

Operating status

Operating

Short description

Serum Life Sciences Ltd is a UK wholly owned subsidiary of Serum Institute of India, functioning as the UK Marketing Authorisation Holder and commercial arm for SIIPL's vaccine and diagnostic portfolio, including the SIILTIBCY® tuberculosis skin test, supplying UK NHS and global immunisation programmes via UN agency partnerships.

Ownership category

akta.pro rank

Product category

Vaccines and Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

akta.pro secondary industries

Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Vaccines & Public Health Product Distribution (CRAOAHAI), Immunization & Vaccine Delivery Programs (BPADAIAB), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)

Keywords

• Vaccine manufacturing
• Tuberculosis diagnostics
• Malaria vaccines
• Global immunization
• Vaccine distribution

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Vaccine and Diagnostic Product Sales: SLS generates revenue through sales of vaccines and diagnostic products manufactured by its parent company Serum Institute of India. The company serves as the UK Marketing Authorisation Holder and facilitates supply to the UK market and global immunisation programmes.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Serum Life Sciences Ltd (SLS) is the UK-based wholly owned subsidiary of Serum Institute of India Pvt. Ltd (SIIPL) that operates as the UK Marketing Authorisation Holder and commercial gateway for vaccines and diagnostic products manufactured by its parent company. The company markets SIILTIBCY® (novel tuberculosis skin test), R21/Matrix-M™ malaria vaccine, COVOVAX™ and COVISHIELD COVID-19 vaccines, BCG vaccines, and routine childhood vaccines to government health systems, UN agencies (UNICEF, PAHO, Gavi, MSF), and the UK NHS.

Product overview

Serum Life Sciences Ltd (SLS) is a wholly owned subsidiary of Serum Institute of India Pvt. Ltd (SIIPL), the world's largest vaccine manufacturer by number of doses produced and sold globally. SLS serves as the UK Marketing Authorisation Holder and facilitates supply of vaccines and diagnostic products to the UK market. The company operates as a sales and regulatory subsidiary supporting the broader SIIPL portfolio, which includes: SIILTIBCY® (novel tuberculosis diagnostic skin test), R21/Matrix-M™ malaria vaccine (WHO-recommended), COVOVAX™ COVID-19 vaccine (WHO EUL), COVISHIELD COVID-19 vaccine, BCG vaccines, and routine childhood vaccines (DTP, MMR, Hib, Hepatitis B, etc.). SLS supports global immunisation programmes through partnerships with UN agencies, reaching populations in more than 100 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• SIILTIBCY®
• R21/Matrix-M™ Malaria Vaccine
• COVOVAX™ COVID-19 Vaccine
• COVISHIELD COVID-19 Vaccine
• BCG Vaccines
• Routine Childhood Vaccines

Quantifiable outcome

• Producing more than 1.5 billion vaccine doses annually
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered moderate and core.

• Bilthoven BiologicalsmoderateStrategic or Co-development Partner · 3 February 2025Bilthoven Biologicals, a Cyrus Poonawalla Group company, inaugurated pandemic preparedness vaccine facilities in February 2025. SLS supports this sister company under the EU pandemic preparedness project EU FAB to ensure vaccine accessibility for Europe during pandemic situations.
• University of OxfordcoreStrategic or Co-development Partner · 15 December 2021£50 million funding commitment from Serum Life Sciences Ltd for the Cyrus Poonawalla Vaccines Research Building at Oxford University. Groundbreaking ceremony held 24 June 2025 marking construction start. Partnership supports Oxford's vaccine research including R21/Matrix-M malaria vaccine and Meningitis-B vaccine development.
• Oxford BiomedicacoreStrategic or Co-development Partner · 22 September 2021Strategic partnership announced on 22 September 2021 with the objective of building long-term manufacturing capacity in the UK. Serum Life Sciences Ltd invested in Oxford Biomedica's capabilities to support vaccine and biologics manufacturing capacity within the United Kingdom.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Merck & Co. (MSD): Major vaccines manufacturer with overlapping portfolio in pediatric and infectious disease vaccines and a leading position in TB diagnostics (QuantiFERON-TB Gold) that competes directly with SIILTIBCY. Comparable UK/EU marketing authorization and global health supply footprint.
• Sanofi Pasteur: Vaccine division of one of the world's largest pharmaceutical companies; competes head-to-head with SII/SLS on pediatric combination vaccines (e.g., hexavalent), travel vaccines, and supplies to Gavi/UNICEF. Operates UK/EU MA infrastructure and runs comparable WHO prequalification programs.
• Pfizer: Global vaccine leader with deep NHS/UNICEF supply relationships and parallel UK/EU MA infrastructure. Comparable in pediatric, COVID-19, and pipeline infectious disease vaccines, with significantly greater scale.

Direct peers

• AstraZeneca: UK-based biopharmaceutical partner of SII on COVISHIELD, with overlapping NHS vaccine supply relationships, similar EU regulatory pathway expertise, and shared focus on global health equity—directly comparable as a UK-headquartered counterpart vaccine partner.
• Novavax: Developer of the Matrix-M adjuvant used in COVOVAX and R21/Matrix-M and a direct technology partner of SII/SLS; comparable UK/EU regulatory pathway and shared commercialization economics on the Nuvaxovid/COVOVAX franchise.
• Qiagen: Holds QuantiFERON-TB Gold Plus, the dominant blood-based TB infection assay globally and the most direct competitor to SIILTIBCY. Highly comparable as a diagnostic company commercializing TB tests through NHS, EU tenders, and global public health channels.
• Bharat Biotech: India-headquartered vaccine manufacturer with comparable WHO-prequalified portfolio (e.g., Covaxin, Rotavac), Gavi/UNICEF supply contracts, and emerging UK/EU regulatory presence. Closest emerging-market peer to SII in scale, pricing strategy, and global health positioning.
• GlaxoSmithKline (GSK): UK-headquartered global vaccine leader with a comparable portfolio of pediatric and travel vaccines, established UK/EU marketing authorization infrastructure, and UN agency supply relationships (UNICEF, Gavi). Direct overlap with SLS in NHS tendering, WHO prequalification, and global immunization distribution.

Emerging players

• Oxford Biomedica: UK cell-and-gene therapy CDMO and named strategic partner of SLS (2021 partnership for UK vaccine manufacturing capacity). Comparable as a UK life-sciences platform partnering with SLS on long-term UK vaccine capacity expansion.
• bioMérieux: Diagnostics company with a TB/mycobacteriology franchise (e.g., BIO-TB, culture-based diagnostics and lab instruments) that competes in the same TB detection market as SIILTIBCY. Comparable UK/EU regulatory pathway and procurement via public health systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Serum Life Sciences